{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:16:40Z","timestamp":1750220200451,"version":"3.41.0"},"publisher-location":"New York, NY, USA","reference-count":24,"publisher":"ACM","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.acm.org\/publications\/policies\/copyright_policy#Background"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,13]]},"DOI":"10.1145\/3545729.3545766","type":"proceedings-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T16:13:55Z","timestamp":1665677635000},"page":"183-188","source":"Crossref","is-referenced-by-count":0,"title":["Thyroid Dland Disorders Associated with Combination of Antiangiogenic Agents and Immune Checkpoint Inhibitors: A Pharmacovigilance Study"],"prefix":"10.1145","author":[{"given":"Lujie","family":"Zhuge","sequence":"first","affiliation":[{"name":"Zhejiang Chinese Medical University, China"}]}],"member":"320","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"e_1_3_2_1_1_1","volume-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine, 366(26), 2443\u20132454","author":"Topalian S. L.","year":"2012","unstructured":"Topalian , S. L. , Hodi , F. S. , Brahmer , J. R. , Gettinger , S. N. , Smith , D. C. , McDermott , D. F. , Powderly , J. D. , Carvajal , R. D. , Sosman , J. A. , Atkins , M. B. , Leming , P. D. , Spigel , D. R. , Antonia , S. J. , Horn , L. , Drake , C. G. , Pardoll , D. M. , Chen , L. , Sharfman , W. H. , Anders , R. A. , Taube , J. M. , \u2026 Sznol , M. ( 2012 ). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine, 366(26), 2443\u20132454 . Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., Pardoll, D. M., Chen, L., Sharfman, W. H., Anders, R. A., Taube, J. M., \u2026 Sznol, M. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine, 366(26), 2443\u20132454."},{"key":"e_1_3_2_1_2_1","doi-asserted-by":"crossref","unstructured":"H.I. Assi A.O. Kamphorst N.M. Moukalled S.S. Ramalingam Immune checkpoint inhibitors in advanced non-small cell lung cancer Cancer 124(2) (2018) 248\u2013261.  H.I. Assi A.O. Kamphorst N.M. Moukalled S.S. Ramalingam Immune checkpoint inhibitors in advanced non-small cell lung cancer Cancer 124(2) (2018) 248\u2013261.","DOI":"10.1002\/cncr.31105"},{"key":"e_1_3_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_3_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2015.35"},{"key":"e_1_3_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2016.04.01"},{"key":"e_1_3_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_3_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011"},{"key":"e_1_3_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_3_2_1_9_1","volume-title":"The future of immune checkpoint therapy.Science 348 (6230), 56\u201361","author":"Sharma P.","year":"2015","unstructured":"Sharma , P. , and Allison , J. P . ( 2015 ). The future of immune checkpoint therapy.Science 348 (6230), 56\u201361 . Sharma, P., and Allison, J. P. (2015). The future of immune checkpoint therapy.Science 348 (6230), 56\u201361."},{"key":"e_1_3_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01173"},{"key":"e_1_3_2_1_11_1","volume-title":"Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Frontiers in immunology.11:1956","author":"Song Y","year":"2020","unstructured":"Song Y , Fu Y , Xie Q , Zhu B , Wang J , Zhang B. ( 2020 ). Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Frontiers in immunology.11:1956 . Song Y, Fu Y, Xie Q, Zhu B, Wang J, Zhang B. (2020).Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Frontiers in immunology.11:1956."},{"key":"e_1_3_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0237"},{"key":"e_1_3_2_1_13_1","unstructured":"U.S. Food and Drug Administration.Questions and answers on FDA's Adverse Event Reporting System(FAERS) https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers [accessed 30 December 2020].  U.S. Food and Drug Administration.Questions and answers on FDA's Adverse Event Reporting System(FAERS) https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers [accessed 30 December 2020]."},{"key":"e_1_3_2_1_14_1","doi-asserted-by":"crossref","unstructured":"Almenoff JS Pattishall EN Gibbs TG DuMouchel W Evans SJ Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007 Aug;82(2):157-66.  Almenoff JS Pattishall EN Gibbs TG DuMouchel W Evans SJ Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007 Aug;82(2):157-66.","DOI":"10.1038\/sj.clpt.6100258"},{"key":"e_1_3_2_1_15_1","doi-asserted-by":"crossref","unstructured":"Qian Y Ye X Du W Ren J Sun Y Wang H Luo B Gao Q Wu M He J. A computerized system for detecting signals due to drug-drug interactions in spontaneous reporting systems. Br J Clin Pharmacol. 2010 Jan;69(1):67-73.  Qian Y Ye X Du W Ren J Sun Y Wang H Luo B Gao Q Wu M He J. A computerized system for detecting signals due to drug-drug interactions in spontaneous reporting systems. Br J Clin Pharmacol. 2010 Jan;69(1):67-73.","DOI":"10.1111\/j.1365-2125.2009.03557.x"},{"key":"e_1_3_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.41.GP216"},{"key":"e_1_3_2_1_17_1","volume-title":"Spectrum of immune checkpoint inhibitors- induced endocrinopathies in cancer patients: a scoping review of case reports. Clin. Diabetes Endocrinol. 5, 1","author":"Tan M. H.","year":"2019","unstructured":"Tan , M. H. Spectrum of immune checkpoint inhibitors- induced endocrinopathies in cancer patients: a scoping review of case reports. Clin. Diabetes Endocrinol. 5, 1 ( 2019 ). Tan, M. H. Spectrum of immune checkpoint inhibitors- induced endocrinopathies in cancer patients: a scoping review of case reports. Clin. Diabetes Endocrinol. 5, 1 (2019)."},{"key":"e_1_3_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0754-2"},{"key":"e_1_3_2_1_19_1","doi-asserted-by":"crossref","unstructured":"Ji HH Tang XW Dong Z Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS. Clin Drug Investig. 2019;39: 319\u201330  Ji HH Tang XW Dong Z Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS. Clin Drug Investig. 2019;39: 319\u201330","DOI":"10.1007\/s40261-018-0735-0"},{"key":"e_1_3_2_1_20_1","doi-asserted-by":"crossref","unstructured":"Barroso-Sousa R Barry WT Garrido-Castro AC Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4:173\u201382.  Barroso-Sousa R Barry WT Garrido-Castro AC Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4:173\u201382.","DOI":"10.1001\/jamaoncol.2017.3064"},{"key":"e_1_3_2_1_21_1","volume-title":"Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat. Arch. Histol. Cytol. 61, 17\u201328","author":"Fan L.","year":"1998","unstructured":"Fan , L. & Iseki , S. Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat. Arch. Histol. Cytol. 61, 17\u201328 ( 1998 ). Fan, L. & Iseki, S. Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat. Arch. Histol. Cytol. 61, 17\u201328 (1998)."},{"key":"e_1_3_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/725410"},{"key":"e_1_3_2_1_23_1","doi-asserted-by":"crossref","unstructured":"Hershman J. M. & Liwanpo L. How does sunitinib cause hypothyroidism? Thyroid 20 243\u2013244 (2010)  Hershman J. M. & Liwanpo L. How does sunitinib cause hypothyroidism? Thyroid 20 243\u2013244 (2010)","DOI":"10.1089\/thy.2010.1620"},{"key":"e_1_3_2_1_24_1","doi-asserted-by":"crossref","unstructured":"Song Y Fu Y Xie Q Zhu B Wang J Zhang B. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Frontiers in immunology. 2020;11:1956.  Song Y Fu Y Xie Q Zhu B Wang J Zhang B. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Frontiers in immunology. 2020;11:1956.","DOI":"10.3389\/fimmu.2020.01956"}],"event":{"name":"ICMHI 2022: 2022 6th International Conference on Medical and Health Informatics","acronym":"ICMHI 2022","location":"Virtual Event Japan"},"container-title":["2022 6th International Conference on Medical and Health Informatics"],"original-title":[],"link":[{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3545729.3545766","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dl.acm.org\/doi\/pdf\/10.1145\/3545729.3545766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T19:02:46Z","timestamp":1750186966000},"score":1,"resource":{"primary":{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3545729.3545766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":24,"alternative-id":["10.1145\/3545729.3545766","10.1145\/3545729"],"URL":"https:\/\/doi.org\/10.1145\/3545729.3545766","relation":{},"subject":[],"published":{"date-parts":[[2022,5,13]]}}}